Literature DB >> 27463503

Chronic Lymphocytic Leukemia in Young Adults: Report of Six Cases Under the Age of 30 Years.

G Lugassy1, V A Boussiotis2, R Ruchlemer3, G A Pangalis2, A Berrebi4, A Polliack3.   

Abstract

We describe six rare patients with B-type CLL under the age of 30 years. All were males and four showed a relatively aggressive clinical course requiring initial chemotherapy at an early stage of their disease. Four of the six patients developed prominent generalized lymphadenopathy accompanied by splenomegaly and a rapid increase in the peripheral blood lymphocyte count or a doubling time of less than 12 months and were symptomatic. Of the six cases, one still has Stage A (0) disease, 16 months after diagnosis and has not yet been treated, while another 29 year old male, initially stage C (3) at diagnosis, progressed rapidly, despite chemotherapy and died after 42 months. Of the remaining four patients all responded well to treatment initially, however one 24 year old male has progressed rapidly from stage A (2) to Stage B (2), 14 months after initial response to chlorambucil and prednisone. Two patients remain in Stage A (0), two and eight years respectively after chemotherapy; while the patient with the longest follow up is currently 39 years old in good partial remission with Stage A (0) disease ten years after initial diagnosis, having responded well to Fludarabine, following a major flare up of his disease recently. The rare phenomenon of young patients with CLL is reviewed and management options relating to new therapeutic approaches for this sub-population of young patients are discussed.

Entities:  

Keywords:  CLL; lymphocytic leukemia; young adults

Year:  1991        PMID: 27463503     DOI: 10.3109/10428199109103402

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  1 in total

1.  A 23-year-old woman with 11q-chronic lymphocytic leukemia.

Authors:  Carlos Eduardo Miguel; Fábio Morato de Oliveira; Sabrina Dias Leite-Cueva; Eduardo Magalhães Rego; Roberto Passetto Falcão
Journal:  Med Oncol       Date:  2010-05-04       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.